Miyashita, Minoru
Bell, Joshua S. K.
Wenric, Stephane
Karaesmen, Ezgi
Rhead, Brooke
Kase, Matthew
Kaneva, Kristiyana
De La Vega, Francisco M.
Zheng, Yonglan
Yoshimatsu, Toshio F.
Khramtsova, Galina
Liu, Fang
Zhao, Fangyuan
Howard, Frederick M.
Nanda, Rita
Beaubier, Nike
White, Kevin P.
Huo, Dezheng
Olopade, Olufunmilayo I.
Funding for this research was provided by:
Susan G. Komen (CURE SAC110026)
American Cancer Society
Article History
Received: 19 July 2022
Accepted: 27 February 2023
First Online: 25 May 2023
Declarations
:
: All analyses were performed using de-identified data; IRB exemption Pro00042950 was obtained from Advarra on April 15, 2020.
: Not applicable.
: E.K., S.W., J.S.K.B., B.R., M.K., K.K., N.B., and F.D.L.V. are employees of Tempus Labs. R.N. serves on the Advisory Board for Astrazeneca, BeyondSpring, Cardinal Health, Fujifilm, Immunomedics/Gilead Infinity, iTeos, MacroGenics, Merck, OBI, Oncosec, and Seattle Genetics, and R.N.’s associated institution has received research funding from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, and Taiho. K.P.W. is a Scientific Advisor and stockholder of Tempus Labs. K.P.W. is chairman and stockholder of Provaxus, Inc. O.I.O. is co-founder at CancerIQ, serves as Scientific Advisor at Tempus, is on the Board of 54gene and received research support from Genentech/Roche and Color Genomics. All other authors declare no competing interest.